tiprankstipranks
Trending News
More News >
Immuron Ltd (IMRN)
NASDAQ:IMRN
Advertisement

Immuron (IMRN) AI Stock Analysis

Compare
197 Followers

Top Page

IMRN

Immuron

(NASDAQ:IMRN)

Rating:46Neutral
Price Target:
$1.50
▼(-14.29%Downside)
Immuron's overall stock score is primarily impacted by its strong revenue growth yet significant challenges in profitability and cash flow, leading to liquidity concerns. The technical analysis presents a neutral outlook with slight downward pressure. The valuation remains unattractive due to a negative P/E ratio and no dividend yield, further weighing down the score.

Immuron (IMRN) vs. SPDR S&P 500 ETF (SPY)

Immuron Business Overview & Revenue Model

Company DescriptionImmuron Limited (IMRN) is a biopharmaceutical company focused on the research, development, and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases. The company's core products are based on its proprietary technology platform that utilizes colostrum-derived polyclonal antibodies. Immuron's primary product, Travelan, is designed to reduce the risk of travelers' diarrhea and is marketed in several countries. The company is also involved in developing treatments for non-alcoholic steatohepatitis (NASH) and Clostridium difficile infections.
How the Company Makes MoneyImmuron makes money primarily through the sale of its commercial product, Travelan, which is sold over-the-counter to travelers seeking to prevent travelers' diarrhea. Revenue is generated from direct sales, distribution agreements, and licensing deals across various international markets. Additionally, Immuron invests in research collaborations and partnerships aimed at expanding its product portfolio, including potential treatments for NASH and Clostridium difficile infections. These partnerships may offer milestone payments and royalties based on the success of development and commercialization efforts. The company's revenue streams are thus a combination of product sales, licensing, and strategic partnerships.

Immuron Financial Statement Overview

Summary
Immuron demonstrates strong revenue growth with a 171.7% increase, but profitability remains a major challenge due to negative net profit margin and high operating expenses. The balance sheet shows financial stability with minimal leverage and a strong equity ratio, but negative cash flow performance raises liquidity concerns.
Income Statement
45
Neutral
The company has shown a significant increase in revenue over the past year, with a revenue growth rate of 171.7%. However, profitability remains a challenge as evidenced by the negative net profit margin of -141.5% and consistently negative EBIT and EBITDA margins. The gross profit margin is relatively strong at 68.1%, indicating good control over direct costs, but overall profitability is heavily impacted by high operating expenses.
Balance Sheet
55
Neutral
The balance sheet exhibits financial stability with a low debt-to-equity ratio of 0.01, suggesting minimal leverage. However, the return on equity is negative at -54.6%, reflecting the company's struggle to generate profits from shareholder investments. The equity ratio stands at 81.7%, indicating a strong equity position relative to total assets, which provides some financial resilience.
Cash Flow
40
Negative
Cash flow performance is weak, with a negative operating cash flow to net income ratio, indicating that the company is not generating enough cash from operations to cover its net income loss. Free cash flow is also negative, and the free cash flow growth rate is -113.7%, showing a declining trend in cash available after capital expenditures.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue4.90M1.80M765.19K145.78K2.52M
Gross Profit3.34M1.31M523.50K94.70K1.83M
EBITDA-6.88M-3.80M-3.08M-8.33M-3.17M
Net Income-6.94M-3.79M-2.85M-8.38M-2.93M
Balance Sheet
Total Assets15.55M21.99M24.86M27.05M6.20M
Cash, Cash Equivalents and Short-Term Investments11.66M18.99M22.11M25.05M3.25M
Total Debt173.50K189.09K209.79K20.50K61.10K
Total Liabilities2.84M2.37M1.68M1.16M558.25K
Stockholders Equity12.71M19.62M23.18M25.90M5.64M
Cash Flow
Free Cash Flow-5.88M-2.50M-3.14M-4.09M-3.17M
Operating Cash Flow-5.88M-2.49M-3.13M-4.08M-3.16M
Investing Cash Flow327.56K-2.74M-10.05K-6.63K-864.00
Financing Cash Flow829.00-35.02K-36.26K26.49M1.17M

Immuron Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.75
Price Trends
50DMA
1.77
Negative
100DMA
1.79
Negative
200DMA
1.89
Negative
Market Momentum
MACD
-0.01
Positive
RSI
47.05
Neutral
STOCH
37.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRN, the sentiment is Negative. The current price of 1.75 is below the 20-day moving average (MA) of 1.77, below the 50-day MA of 1.77, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.05 is Neutral, neither overbought nor oversold. The STOCH value of 37.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMRN.

Immuron Risk Analysis

Immuron disclosed 62 risk factors in its most recent earnings report. Immuron reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, the price of our ordinary shares and ADSs could decline significantly and raising capital could be more difficult. Q2, 2024
2.
A material breach in security relating to the Company's information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation. Q2, 2024

Immuron Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
48
Neutral
$13.90M-194.84%48.91%
46
Neutral
$12.41M-52.79%82.77%-87.95%
41
Neutral
$23.86M-160.26%19.21%
38
Underperform
$18.44M-60.06%8.99%
37
Underperform
$10.96M82.91%64.20%73.71%
37
Underperform
$11.87M-105.79%-82.54%-12.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMRN
Immuron
1.74
-0.54
-23.68%
RLMD
Relmada Therapeutics
0.66
-3.39
-83.70%
BTAI
Bioxcel Therapeutics
1.73
-16.99
-90.76%
CTXR
Citius Pharmaceuticals
1.69
-21.58
-92.74%
HOOK
Hookipa Pharma
0.91
-5.41
-85.60%
PRTG
Portage Biotech Inc
5.91
1.98
50.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025